 Based on locally available IPD data and a prior immunogenicity study in Kathmandu, pneumococcal conjugate vaccination utilising PCV10 with two priming doses at 6 and 14 weeks followed by a 9-month booster has been demonstrated to be the WHO preferred schedule in comparison to a three-dose prime only schedule. However the WHO have also recommended the introduction of a single dose of IPV at 14 weeks of age in order to eradicate poliomyelitis serotype 2 vaccine strain disease. Local experts anticipate a poor uptake of vaccine at 14 weeks of age due to the increase in number of injections from one to three at this time-point. The Nepali government has thus suggested moving the 14 weeks PCV10 priming dose to the earlier 10 week time-point, however there are no immunogenicity data to support this decision. Therefore this study will aim to compare the immunogenicity of giving the two PCV10 priming doses at 6 and 10 weeks to that of 6 and 14 weeks. In addition this study will also evaluate the adverse event profile following the 14 weeks of age visit in the two treatment arms. 